Antonio Carrasco Lorenzo

Dr. Antonio Carrasco Lorenzo

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NCNatalia Castrejon
Natalia Castrejon
RMRoberto Martin
Roberto Martin
ALAntonio Carrasco Lorenzo
Antonio Carrasco Lorenzo
PCPaola Castillo
Paola Castillo
AGAdriana Garcia
Adriana Garcia
Cristina TeixidóCristina Teixidó
Cristina Teixidó
Targeted NGS allows a fast and efficient multi-gene analysis and the detection of key gene aberrations in melanoma. In this study, we aim to describe the genetic alterations in a series of 87 melanoma cases using the oncomine focus assay (OFA), relate these results with the clinicopathological features of the patients, and compare them with our previous study results in which we used a smaller panel, the oncomine solid tumor (OST) DNA kit. Patients diagnosed with advanced melanoma at our center from 2020 to 2022 were included and DNA and RNA were extracted for sequencing. Common mutated genes were BRAF (29%), NRAS (28%), ALK, KIT, and MAP2K1 (5% each). Co-occurring mutations were detected in 29% of the samples, including BRAF with KIT, CTNNB1, EGFR, ALK, HRAS, or MAP2K1. Amplifications and rearrangements were detected in 5% of cases. Only BRAF mutation showed a significant statistical association with sun exposure. For patients with a given genetic profile, the melanoma survival and recurrence-free survival rates were equivalent, but not for stage and LDH values. This expanded knowledge of molecular alterations has helped to more comprehensively characterize our patients and has provided relevant information for deciding the best treatment strategy.

8 April 2026 in Virchows Archiv
Verified
Journal Article
Open access
ALAntonio Carrasco Lorenzo
Antonio Carrasco Lorenzo
JLJoan Lop
Joan Lop
NCNatalia Castrejon
Natalia Castrejon
AGAdriana García-Herrera
Adriana García-Herrera
RARaquel Albero-González
Raquel Albero-González
Cristina TeixidóCristina Teixidó
Cristina Teixidó
Mucosal melanoma represents a rare, aggressive malignancy with limited therapeutic options and sparse data on prognostic markers. Here, we assess histopathologic and molecular parameters influencing survival to identify features applicable in routine diagnostics. A retrospective single-centre clinicopathological study of 51 patients diagnosed with mucosal melanoma (genitourinary, head and neck and gastrointestinal) between 2016 and 2024 was performed. Histopathological parameters, including tumour-infiltrating lymphocytes, were assessed by pathologists with expertise on melanocytic lesions. Molecular data derived from previously performed next-generation sequencing panels targeting common oncogenic drivers were retrieved from pathology records. Molecular and histopathological findings were correlated with clinical data and survival outcomes. The findings highlight the prognostic relevance of proliferative activity and residual in situ disease. Disease-free survival was significantly reduced in patients with metastatic (M1) status, ulceration, ≥10 mitoses/mm 2 and amelanotic tumours on univariate analysis, although none of these variables remained significant in multivariate models. Overall survival (OS) was significantly lower in cases with M1 status and in the presence of an in situ component in both univariate and multivariate analyses; high mitotic activity showed a nonsignificant trend towards reduced OS in multivariate analysis. NRAS was the most frequent mutation, followed by ARID1A , CDK4 , CDKN2A , JAK2 and MYC , without a significant association with survival. These results emphasise the prognostic value of mitotic index and surgical completeness, while confirming the marked molecular heterogeneity of mucosal melanoma and the lack of a single dominant actionable alteration.